PUBLISHER: DataM Intelligence | PRODUCT CODE: 1542870
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1542870
Global Artificial Blood Market - 2024-2031
Overview
Global Artificial Blood Market reached US$ 3760.00 million in 2023 and is expected to reach US$ 7194.83 million by 2031, growing at a CAGR of 8.7% during the forecast period 2024-2031.
While true blood performs different functions, artificial blood is designed to transport oxygen and carbon dioxide through the body. Based on the type of artificial blood it can be produced in different ways including synthetic production, chemical isolation, or recombinant biochemical technology.
The advantages of artificial blood include providing critical benefits over allogenic blood transfusions by delivering increased oxygen-carrying capacity, saving time in trauma cases and battlefield scenarios, higher life than regular blood, minor chances of the disease spreading, and the ability to manufacture larger quantities of blood. Artificial blood is available in the market in terms of hemoglobin-based oxygen carriers and perfluorocarbon emulsions.
Market Dynamics: Drivers & Restraints
Rising advancements in research and development
The rising research and development are expected to drive the market growth. Ongoing research is focused on addressing safety issues of artificial blood, such as immunological reactions and toxicity. Advancements in R&D can result in safer blood replacements with fewer adverse effects, increasing physician and patient acceptance of their use. Researchers are focusing on the development of products that could mimic the blood with fewer side effects.
For instance, in November 2022, a world-first clinical trial funded and supported by NIHR started giving lab-grown red blood cells to people. The RESTORE clinical trial (REcovery and survival of STem cell Originated REd cells) was initiated by the NIHR Blood and Transplant Research Unit in Red Blood Cell Products.
Additionally, on July 18, 2024, Bioxytran, Inc. announced a Joint Venture with the Heme Foundation to develop a Universal Oxygen Carrier ("UOC") as an alternative to blood transfusions.
And, on July 27, 2024, Nara Medical University stated that it will begin a clinical study of artificial red blood cells that can be stored for transfusions in times of emergency in Japan by next March 2025.
Adverse effects of artificial blood
Adverse effects of hemoglobin-based oxygen carriers include hypertension, abdominal pain, skin rash, diarrhea, jaundice, hemoglobinuria, oliguria, fever, stroke, and laboratory abnormalities such as an increase in lipase. These adverse reactions could reduce the adoption of artificial blood in surgical procedures and for transfusions.
Market Segment Analysis
The global artificial blood market is segmented based on product type, source, process, application, end-user, and region.
Hemoglobin-based oxygen carriers segment is expected to dominate the market share
Hemoglobin-based oxygen carriers segment is expected to hold a significant position in the market share due to a variety of factors. HBOCs have been developed to efficiently transport and release oxygen, which is comparable to the function of natural hemoglobin in red blood cells. This makes them extremely effective for oxygen delivery, especially in situations of emergency.
HBOCs can be employed in a variety of medical settings, including operations, injuries, and anemia therapies. Their ability to adapt improves their commercial potential across numerous applications. Significant R&D investment is being made to improve the efficacy and safety features of HBOCs, resulting in advances that can increase their adoption in clinical settings. Thus, the above factors are expected to hold a significant position in the market share.
Market Geographical Share
North America is expected to hold a significant position in the artificial blood market share
North America dominates the global artificial blood market during the forecast period owing to the rise in trauma deaths due to excessive blood loss before admission, and an increase in the prevalence of anemia and blood-related disorders across the region leading to the development of novel artificial blood.
The rising studies in the development of artificial blood in the region to substitute the original human blood and use it for the transfusion processes in the anemic and other patients are expected to drive market growth in the region.
For instance, according to a publication by UMSOM, UMSOM will manage the $46.4 million four-year research project administered by the Defense Advanced Research Projects Agency (DARPA), in collaboration with the University of Maryland School of Pharmacy (UMSOP) and more than a dozen universities and biotech companies. A Physician-scientist of UMSOM will head the new federally-funded research program to develop and test a whole blood product, storable at room temperature, that can be used to transfuse wounded soldiers in the field within 30 minutes of injury, potentially saving thousands of lives
Market Segmentation
By Product Type
Hemoglobin-based Oxygen Carriers
Perfluorocarbon Emulsion
By Source
Human Hemoglobin
Animal Hemoglobin
Stem Cells
Synthetic Polymers
Microorganisms
Others
By Process
Synthetic Production
Chemical Isolation
Recombinant Biochemical Technology
By Application
Anemia
Organ Transplantation
Injuries & Trauma
Cardiovascular Diseases
Maternal Conditions
Others
By End-User
Hospitals
Clinics
Blood Banks
Research Institutes
Others
By Region
North America
The U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the market include Hemarina, KaloCyte, Inc., SpheriTech Limited, and Hemoglobin Oxygen Therapeutics LLC among others.
Why Purchase the Report?
To visualize the global artificial blood market segmentation based on product type, source, process, application, end-user, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of artificial blood market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.
The global artificial blood market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Product Type
- 3.2. Snippet by Source
- 3.3. Snippet by Process
- 3.4. Snippet by Application
- 3.5. Snippet by End-User
- 3.6. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Rising advancements in research and development
- 4.1.2. Restraints
- 4.1.2.1. Adverse effects of artificial blood
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Reimbursement Analysis
- 5.6. Patent Analysis
- 5.7. SWOT Analysis
- 5.8. DMI Opinion
6. By Product Type
- 6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
- 6.2. Hemoglobin-based Oxygen Carriers*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Perfluorocarbon Emulsion
7. By Source
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
- 7.1.2. Market Attractiveness Index, By Source
- 7.2. Human Hemoglobin*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Animal Hemoglobin
- 7.4. Stem Cells
- 7.5. Synthetic Polymers
- 7.6. Microorganisms
- 7.7. Others
8. By Process
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
- 8.1.2. Market Attractiveness Index, By Process
- 8.2. Synthetic Production*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Chemical Isolation
- 8.4. Recombinant Biochemical Technology
9. By Application
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
- 9.2. Anemia*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Organ Transplantation
- 9.4. Injuries & Trauma
- 9.5. Cardiovascular Diseases
- 9.6. Maternal Conditions
- 9.7. Others
10. By End-User
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.1.2. Market Attractiveness Index, By End-User
- 10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Clinics
- 10.4. Blood Banks
- 10.5. Research Institutes
- 10.6. Others
11. By Region
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
- 11.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
- 11.2.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.2.3.1. The U.S.
- 11.2.3.2. Canada
- 11.2.3.3. Mexico
- 11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
- 11.3.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
- 11.3.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.3.4.1. Germany
- 11.3.4.2. UK
- 11.3.4.3. France
- 11.3.4.4. Italy
- 11.3.4.5. Spain
- 11.3.4.6. Rest of Europe
- 11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
- 11.4.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
- 11.4.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.4.4.1. Brazil
- 11.4.4.2. Argentina
- 11.4.4.3. Rest of South America
- 11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
- 11.5.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
- 11.5.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.5.4.1. China
- 11.5.4.2. India
- 11.5.4.3. Japan
- 11.5.4.4. South Korea
- 11.5.4.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
- 11.6.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
- 11.6.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis
13. Company Profiles
- 13.1. Hemarina *
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
- 13.2. KaloCyte, Inc.
- 13.3. SpheriTech Limited
- 13.4. Hemoglobin Oxygen Therapeutics LLC. (*LIST NOT EXHAUSTIVE)
14. Appendix
- 14.1. About Us and Services
- 14.2. Contact Us
